Source: GlobeNewswire

Press Release: SCYNEXIS : SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET.

Read full article »
Annual Revenue
$100K-5.0M
Employees
25-100
Marco Taglietti's photo - President & CEO of SCYNEXIS

President & CEO

Marco Taglietti

CEO Approval Rating

88/100

Read more